Lexeo Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
Condensed Statements of Cash Flows
(Unaudited, in thousands)
| Six Months Ended June 30, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(58,759) | $(42,920) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Reduction in the carrying amount of ROU assets, operating | 729 | 661 | ||
| Reduction in the carrying amount of ROU assets, finance | 160 | 165 | ||
| Stock-based compensation expense | 6,768 | 5,177 | ||
| Depreciation and amortization expense | 122 | 146 | ||
| Non-cash gain on long-term investment | (3,390) | - | ||
| Amortization of premium on investments | 46 | - | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | (2,566) | 660 | ||
| Accounts payable | 13,507 | 1,698 | ||
| Accrued expenses and other current liabilities | (4,822) | 19 | ||
| Lease liabilities, operating | (721) | (636) | ||
| Lease liabilities, finance | (9) | 11 | ||
| Net cash used in operating activities | (48,935) | (35,019) | ||
| Cash flows from investing activities: | ||||
| Purchase of internal use software | - | (13) | ||
| Purchase of property and equipment | (108) | (398) | ||
| Purchases of investments | (55,366) | - | ||
| Proceeds from maturities of investments | 31,900 | - | ||
| Net cash used in investing activities | (23,574) | (411) | ||
| Cash flows from financing activities: | ||||
| Proceeds from exercise of stock options | - | 429 | ||
| Payments on finance leases | (281) | (183) | ||
| Proceeds from common stock issuances under 2023 ESPP | 170 | - | ||
| Treasury stock repurchase | - | (13) | ||
| Proceeds from issuance of common stock upon March 2024 Private Placement Offering | - | 94,999 | ||
| Third-party commissions and offering costs incurred upon March 2024 Private Placement Offering | - | (6,287) | ||
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement Offering | 79,999 | - | ||
| Third-party commissions and offering costs incurred upon May 2025 Private Placement Offering | (6,917) | - | ||
| Net cash provided by financing activities | 72,971 | 88,945 | ||
| Net change in cash, cash equivalents and restricted cash | 462 | 53,515 | ||
| Cash, cash equivalents and restricted cash at beginning of period | 38,266 | 124,718 | ||
| Cash, cash equivalents and restricted cash at end of period | $38,728 | $178,233 | ||
| Supplemental disclosure of non-cash activities | ||||
| Unpaid offering costs included in accounts payable and accrued expenses | $905 | $389 | ||
| Unrealized gain on investments | $90 | $ | - | |
| Issuance costs related to convertible debt included in accounts payable and accrued expenses | $ | - | $24 | |
| Net property and equipment purchased in the current period included in accounts payable (net property and equipment purchased in the prior period previously included in accounts payable and paid in the current period) | $101 | $(116) | ||
| Finance lease right-of use assets and finance lease liabilities recognized | $ | - | $22 | |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities | $25 | $28 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.